

To: Hospital CFOs
Cc: Hospital Quality Liaisons, Case-Mix Liaisons
From: HSCRC Quality Team
Date: March 2, 2026
Re: Maryland Rate Year 2028 Quality Based Reimbursement Program Measure Standards, Scaling Determination, and other Methodology Updates

Joshua Sharfstein, MD
Chairman

James N. Elliott, MD
Vice-Chairman

Jonathan Blum, MPP

Ricardo R. Johnson

David N. Maine, MD

Nicki McCann, JD

Farzaneh Sabi, MD

Jonathan Kromm, PhD
Executive Director

William Henderson
Director
Medical Economics & Data Analytics

Gerard J. Schmith
Director
Revenue & Regulation Compliance

Claudine Williams
Director
Healthcare Data Management & Integrity

This memo summarizes the Quality Based Reimbursement (QBR) Program that will impact hospital rates in Rate Year (RY) 2028.

INTRODUCTION

On January 14, 2026, the Commission approved the staff recommendations for updating the Quality-Based Reimbursement (QBR) Program for RY 2028.

Under the new AHEAD model, which began on January 1, 2026, the hospitals will be moving to the CMS Hospital quality programs for RY 2029 or RY 2030. In order to assist with this transition, the [RY 2028 Policy](#) has several changes to the measures and domain weights to better align the QBR program with the CMS national Hospital Value Based Purchasing (HVBP) program. Furthermore, the RY 2028 policy provides timeline options for transitioning fully to the CMS HVBP for Medicare FFS global budgets. The HSCRC will continue to implement a state QBR program that will be applicable to hospital global budgets for beneficiaries of all other payers (i.e., non-Medicare FFS). The state programs will align with the CMS policies to reduce administrative burden, but maintain the ability to address statewide priorities, including areas of poor performance and/or quality concerns for Medicaid or commercial payers.

The approved RY2028 recommendations are as follows:

1. Update Domain Weighting as follows for determining hospitals' overall performance scores: Person and Community Engagement (PCE) - 38 percent, Safety (NHSN measures) - 31 percent , Clinical Care - 31 percent
2. Continue to hold 2 percent of inpatient revenue at-risk (rewards and penalties) and set the pre-set revenue adjustment scale of 0 to 80 percent with cut-point at 32 percent.
 - a. Retrospectively evaluate the preset cut-point using more recent data to calculate national average score for RY 2027 and RY 2028.
 - b. Based on concurrent analysis of national hospital performance, adjust the RY26 QBR cut-point to 32% to reflect the impact of using pre-COVID performance standards and to ensure that Maryland hospitals are penalized or rewarded relative to national performance.
3. Continue collaboration with CRISP and other partners on infrastructure to collect hospital Electronic Clinical Quality Measures (eCQM) and Core Clinical Data Elements (CCDE) for hybrid measures; add a bonus incentive of \$150,000 in hospital rates for hospitals that fully meet the State-specified expedited reporting timeline, provided that all required measures are reported.

EXEMPTIONS FROM CMS HOSPITAL QUALITY PROGRAMS

Exemptions from the CMS hospital quality programs enables Maryland to operate programs with incremental revenue adjustment scales established prospectively, wherein all hospitals have the opportunity to earn rewards based on their performance. As required, the HSCRC has requested and received approvals for Hospital Value-Based Purchasing (HVBP) exemptions since FY 2013, and for the Hospital Acquired Complication Reduction and Hospital Readmission Reduction Programs (HACRP and HRRP) since FY 2021 (with inception of the TCOC model). Staff will disseminate updates after CMS has responded to our FFY 2026 quality programs exemption request allowing the state to continue to operate the Quality Based Reimbursement, Maryland Hospital Acquired Conditions, and Readmission Reduction Incentive programs.

RY 2028 QBR DOMAIN WEIGHTS, MEASURES, AND MONITORING UPDATES

The updated final policy domain and measure weight details are provided below in Figure 1 in comparison to the CMS HVBP program.

Figure 1. QBR RY 2028 Domain and Measure Weights and Data Sources

Domains and Measures	QBR Domain and Measure Weights	CMS HVBP Domain Weights
PCE Domain	38%	25%
HCAHPS Top Box Scores	20%	✓
HCAHPS Consistency	5%	✓
ED Length of Stay	10%	N/A
TFU Medicaid (Medicaid Claims)	3%	N/A
Clinical Care Domain	31%	25%
Inpatient Mortality (HSCRC Case Mix)	13%	N/A
30-Day All-payer Mortality (HSCRC Case Mix and Maryland Vital Statistics Death Records)	13%	N/A
THA/TKA Complications	5%	✓
30-Day Medicare Condition-specific Mortality (Medicare Claims)	N/A	✓
Safety Domain	31%	25%
CAUTI (Chart abstracted CMS Care Compare)	5.2%	✓
C. Diff (Chart abstracted CMS Care Compare)	5.2%	✓
SSI, Hysterectomy and Colon (Chart abstracted CMS Care Compare)	5.2%	✓
CLABSI (Chart abstracted CMS Care Compare)	5.2%	✓
MRSA (Chart abstracted CMS Care Compare)	5.2%	✓
Severe Sepsis and Septic Shock: Management	5%	✓

Domains and Measures	QBR Domain and Measure Weights	CMS HVBP Domain Weights
Bundle (Chart abstracted, CMS Care Compare)		
Medicare Spending Per Beneficiary	N/A	25%

The updated policy also notes that the following data would be monitored:

- Timely Follow-Up (TFU) for Medicare
- TFU Disparities for Medicare
- Sepsis Dashboard: Sepsis mortality and readmissions, Sep-1 measure–Early Management Bundle, Severe Sepsis/Septic Shock (report launching in February 2026)
- Digital Measures: Electronic Clinical Quality Measures (eCQM) and Hybrid Measures.

HSCRC staff will notify hospitals as monitoring reports are implemented and available on the CRISP Reporting Services portal.

The RY 2028 policy also removes the HCAHPS Linear measures from payment and moves the all-payer AHRQ Patient Safety Index (PSI-90) composite to the MHAC program.

Digital Measures Reporting Requirements

The updated policy included a recommendation for hospitals to continue to submit digital quality measures data to HSCRC with a bonus of \$150K awarded to hospitals that fully comply with the RY 2028 measures submission and expedited reporting timelines. For CYs 2024- 2026, HSCRC and CMS require submission of QRDA I files for the eCQMs and Hybrid measure Core Clinical Data Elements (CCDE) as listed below in Figure 2. For additional information about Maryland's work in this area, please refer to the **updated memorandum issued by HSCRC in February 2026 outlining CY 2026 Digital Measures reporting requirements** distributed to Maryland hospitals and uploaded to the HSCRC digital quality measures data page on the [CRISP website](#).

Figure 2. CMS-Maryland Digital Measures/ eCQM Reporting Measures

Reporting Period	CMS Measures	Maryland Measures
CY 2026	Eight required eCMQs- -Safe Use of Opioids-Concurrent Prescribing (CMS-506) -Cesarean Birth (PC-02) -Severe Obstetric Complications (PC-07) -Hospital Harm-Severe Hyperglycemia (HH-Hyper) -Hospital Harm- Severe Hypoglycemia (HH-Hypo) Three self-selected eCQMs	Eight required eCMQs- -Safe Use of Opioids-Concurrent Prescribing (CMS-506) -Cesarean Birth (PC-02) -Severe Obstetric Complications (PC-07) -Hospital Harm-Severe Hyperglycemia (HH-Hyper) -Hospital Harm- Severe Hypoglycemia (HH-Hypo) Three self-selected eCQMs
July 2025-June 2026	CCDE for two hybrid measures for Medicare: -30-day mortality -30-day readmissions	CCDE for two hybrid measures for Medicare and for all-payer for patients aged 18 and older: -30-day mortality -30-day readmissions
July 2026-June 2027	CCDE for two hybrid measures for Medicare: -30-day mortality -30-day readmissions	CCDE for two hybrid measures for Medicare and for all-payer for patients aged 18 and older: -30-day mortality -30-day readmissions

Hospitals that do not qualify for the (PC-02 and PC-07) obstetric measures should submit zero denominators in the QRDA-1 files for those measures. In the case of self-selected measures, hospitals must commit to reporting the same measures for each of the four quarters in the reporting period.

QBR MEASUREMENT PERIODS

The base and performance measurement periods used for the QBR program for RY 2028 are illustrated below in Figure 3.

Figure 3. QBR RY 2028 Base and Performance Periods

Rate Year (Maryland Fiscal Year)	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	Q3-25	Q4-25	Q1-26	Q2-26	Q3-26	Q4-26	Q1-27	Q2-27	Q3-27	Q4-27	Q1-28	Q2-28	Q3-28	Q4-28			
Calendar Year	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	Q3-25	Q4-25	Q1-26	Q2-26	Q3-26	Q4-26	Q1-27	Q2-27	Q3-27	Q4-27	Q1-28	Q2-28			
Quality Based Reimbursement Program (QBR)					Base Period: Hospital Compare (HCAHPS measures, All NHSN Measures, SEP-1 Bundle)							Performance Period: Hospital Compare (HCAHPS measures, All NHSN Measures, SEP-1 Bundle)							Rate Year Impacted by QBR Results						
							Base Period: QBR IP and 30-Day Mortality, Medicaid Timely Follow-Up						Performance Period: QBR IP and 30-Day Mortality, Medicaid Timely Follow-Up												
									Base Period: Emergency Department Length of Stay						Performance Period: Emergency Department Length of Stay										
		Performance Period: THA/TKA Complications*																							
*Base Period for THA/TKA Complications is CY 2018 Q2- CY 2021 Q1																									

MARYLAND EXTRAORDINARY CIRCUMSTANCES EXCEPTION PROCESS

HSCRC notes that CMS has developed an Extraordinary Circumstances Exception (ECE) process for hospitals under the Inpatient Prospective Payment System (IPPS) that experience circumstances beyond their control that impacts the hospital's ability to meet quality reporting or payment program requirements. Since the CMS ECE process is not applicable for Maryland hospitals, HSCRC has developed a similar process for Maryland facilities under the purview of the HSCRC Rate Setting system to request an exception from HSCRC or CMS quality reporting and payment program requirements due to extraordinary circumstances beyond the control of the facility. A link to the process and form may be found on the [Quality page](#) on the HSCRC website.

QBR SCORE CALCULATIONS AND PERFORMANCE STANDARDS FOR RY 2028

To the extent possible, HSCRC continues to align the QBR program data, scoring calculations, measures list and performance standards with the HVBP program. Key points regarding this methodology are outlined below.

- HSCRC will use the data submitted to CMS for the Inpatient Quality Reporting program and posted to Care Compare for calculating hospital performance scores for all measures with exception of: the Inpatient Mortality, 30-Day Mortality, and Emergency Department Length of Stay measures, which are calculated using HSCRC Case-Mix data; and the Timely Follow-Up after Discharge for Acute Exacerbation of Chronic Conditions measure which is calculated using Medicaid claims data.
 - NOTE: If NHSN data are unavailable on CMS Care Compare for the relevant time periods for some or all hospitals, the HSCRC may obtain these data directly from CMS, or may download the data directly from the NHSN by MHCC. Results from MHCC may be pulled at a different time and may not match CMS data.
- CMS rules will be used when possible for minimum measure requirements for scoring a domain. HSCRC will proportionally readjust domain weighting if a measurement domain is missing for a hospital. Hospitals must be eligible for an HCAHPS score in the PCE domain (i.e., must have at least 100 completed surveys in the performance period) to be included in the program.

- Mortality—hospital Inpatient and 30-day all-payer mortality summary reports and case-level data are provided to hospitals quarterly at a minimum based on preliminary data and quarterly based on final data. Reports are available on the CRS Portal. Appendix A contains the specifications for the Maryland Mortality measures.
- For hospitals with measures that have no data in the base period, staff reserves the right to assess hospitals on attainment-only, since the HSCRC will be unable to calculate improvement scores.
- For hospitals that have measures with data missing from Care Compare for the base and performance periods, staff reserves the right to give hospitals a score of zero for these measures. It is imperative, therefore, that hospitals review their data as soon as it is available and contact CMS with any concerns related to preview data or issues with posting data to Care Compare, and to alert HSCRC staff in a timely manner if issues cannot be resolved.
- The performance standards for each of the Safety, Clinical Care, and Person and Community Engagement measures for RY 2028 are listed below in Figure 4.
 - NOTE: In prior years, CMS has adjusted the HVBP thresholds and benchmarks mid-year for certain measures. Should any HVBP measure included in the RY 2028 QBR program be updated, HSCRC will notify industry and provide an updated calculation sheet at that time.
- Staff anticipates that the following will be provided via the CRISP Reporting Services (CRS) Portal no later than July, with some components published sooner:
 - The calculation workbook which contains a worksheet for each domain for hospitals to use to calculate and monitor their scores, a list of included APR-DRGs in the IP mortality measure, and associated thresholds/benchmarks for each measure.
 - The measures where the standards indicate TBD in Figure 4 below.

Figure 4. QBR Performance Standards for RY 2028

<u>Safety Domain</u>		
Measure Short Name	Achievement Threshold	Benchmark
CAUTI*^	0.443	0.0
CLABSI*^	0.519	0.0
CDI*^	0.314	0.0
MRSA Bacteremia*^	0.596	0.0
Colon and Abd Hysterec SSI*^	0.73 0.907	0.0 0.0
SEP-1^	0.635714	0.86454

* Lower values represent better performance.

^Calculated using CY 2024 data.

<u>Clinical Care Domain</u>		
Measure Short Name	Achievement Threshold	Benchmark
Inpatient Mortality	TBD	TBD
30-Day Mortality	TBD	TBD
THA/TKA*	0.019126	0.013911

*These performance standards have been calculated with the inclusion of COVID-19 data.

<u>Person and Community Engagement</u>			
HCAHPS Survey Dimension	Floor (minimum)	Achievement Threshold	Benchmark
Nurse Communication	57.00	77.81	86.65
Doctor Communication	55.70	77.79	86.52
Medication Communication	37.55	58.47	70.19
Hospital Cleanliness & Quietness	40.30	64.05	78.01
Discharge Information	65.76	86.34	91.63

Overall Hospital Rating	35.22	69.45	84.37
ED Length of Stay*		0	-5% or -10%
TFU Medicaid		TBD	TBD

*If in the base, a hospital performs better than the statewide median LOS (i.e., 562 mins) then their benchmark is -5% and if they performed worse than the statewide median LOS then their benchmark is 10%.

QBR REWARDS- PENALTIES REVENUE ADJUSTMENT SCALING FOR RY 2028

The preset scale for earning rewards and penalties for RY 2028 uses a full distribution of potential scores (scale of 0-80 percent), and a score cut-point of 32 percent, down from 41 percent in previous years, for rewards and penalties. The cut-point may be adjusted retrospectively based on analysis of actual national performance. The maximum reward for QBR will remain at 2%, and the maximum penalty remains at 2%. The preset scale is included as Appendix B of this memorandum.

For any questions, please email hsrcr.quality@maryland.gov.

Appendix A: RY 2025 Maryland Mortality Measure Specifications

Mortality Reporting

Hospitals will be provided with summary level quarterly reports based on preliminary and final HSCRC case-mix data. In addition, case-level detailed files will be provided to each hospital. These summary and case level reports will be posted through the CRISP Reporting Services portal.

Specifications: Inpatient Mortality Rates using 3M, Health Information Systems Risk of Mortality Adjustment

As 3M Risk of Mortality (ROM) categories--which comprise four levels similar to severity of illness classifications used in the All Patient Refined Diagnosis Related Group (APR DRG) payment classification system-- account for risk adjustment for deaths in the hospital, the ROM may provide an appropriate measure of hospital mortality with a broader focus. 3M APR DRGs and ROM are also used as the risk adjustment methodology for other mortality measures, such as those developed by the Agency for Healthcare Research and Quality.

Exclusions

The following categories are removed from the denominators and therefore not included in the mortality rate calculations (excluded from both mortality counts and denominator):

1. APR-DRGs that are NOT in the 80% of cumulative deaths after removing all the exclusions. DRGs are chosen without palliative care discharges and then discharges with palliative care for selected DRGs are added back. All DRGs in the measure that have the same number of observed deaths as the DRG at the 80 percent cut point are included.
2. APR-DRG ROM with a state-wide cell sizes below 20 after removing all the exclusions
3. Rehab hospitals (provider IDs that start with 213)
4. Hospitals without HCAHPS (RY 2021: Levindale, UMROI, McCready)
5. Transfers to other acute hospitals (PAT_DISP=discharge destination 02,05)
6. Age and sex unknown
7. Hospice (Daily service of 10, DAILYSER=10)
8. University of Maryland Shock Trauma Patients (daily service=02, and trauma days>0)

9. Left Against Medical Advice admissions: (PAT_DISP=07).
10. Trauma and Burn admissions: Admissions for multiple significant trauma (MDC=25) or extensive 3rd degree burn (APR DRG = 841 "Extensive 3rd degree burns with skin graft" or 843 "Extensive 3rd degree or full thickness burns w/o skin graft")
11. Error DRG: Admissions assigned to an error DRG 955 or 956
12. Other DRG: Admissions assigned to DRG 589 (Neonate BWT <500G or GA <24 weeks), 591 (NEONATE BIRTHWT 500-749G W/O MAJOR PROCEDURE), 196 (cardiac arrest) due to high risk of mortality in these conditions
13. "APR DRG 004 (Tracheostomy w MV 96+ hours w extensive procedure or ECMO); starting in RY 2022, remove discharges with primary or secondary procedure code for ECMO ("5A1522F", "5A1522G", "5A1522H", "5A15223"))
14. Medical (non-surgical) Malignancy admissions: Medical admissions with a principal diagnosis of a major metastatic malignancy (see calculation sheet for list of medical malignancies)

Adjustments

The Maryland inpatient hospital mortality measure was developed in conjunction with the Performance Measurement workgroup and other stakeholders. Based on this stakeholder input mortality is assessed using a regression model that adjusts for the following variables:

1. Admission APR DRG with Risk of Mortality (ROM)
2. Age (as a continuous variable) and age squared
3. Gender
4. Palliative Care Status (ICD-10 code = Z51.5)
5. Transfers from another institution defined as source of admission codes (SOURCADM) of
04 = FROM (TRANSFER) A DIFFERENT HOSPITAL FACILITY (INCLUDES TRANSFERS FROM ANOTHER ACUTE CARE HOSPITAL (ANY UNIT), FREESTANDING EMERGENCY DEPARTMENT, MIEMSS-DESIGNATED FACILITY). NOT LIMITED TO ONLY IP SERVICES.

Specifications: 30 Day Mortality Rates

Overview

The measure is a hospital-wide, 30-day risk adjusted mortality rate. It is adapted from a measure developed by a team from Yale University Medical School for use by CMS to measure hospital performance for Medicare cases. This HSCRC measure supplements the inpatient mortality measure currently in use as part of the QBR program. The measure has been adapted for use with the HSCRC's all payer data for the state of Maryland and with objectives of Maryland's quality-based performance programs.

Data sources

Data sources for the measure are used to identify index hospital stays and their characteristics, the mortality outcome, and patient characteristics that result in exclusions.

- HSCRC hospital data: Contains hospital stay records, dates, disposition, admission source, diagnoses and procedures
- CMS and Medicaid hospice data: identifies patients participating in hospice programs and dates of participation
- Maryland vital statistics data: identifies individuals' dates of death

These inputs are linked by the field CRISP EID (a unique identifier which can be linked to all three sources). In addition, the code takes as inputs the lists of ICD-10 diagnosis and procedure codes and crosswalks between these codes and Clinical Classifications Software (CCS) diagnostic and procedure categories (provided below).

Inclusion

Patients ages 95 and younger residing in Maryland and treated in Maryland hospitals who are discharged during the study period are included.

Exclusion

Stays are excluded based on hospice enrollment, All Patients Refined Diagnosis Related Groups (APR DRG) assignment, disposition and death information, principal diagnosis, and random selection for patients with multiple admissions.

- Hospice: patients enrolled before, during, or within 30 days after admission, discharged to hospice are excluded

- If DAILYSER = '10' (HOSPICE) then hospice1=1, where DAILYSER is the Daily Service value from CaseMix IP dataset
- If (DISCDATE < '01JUL2018'D and PAT_DISP in ("29", "53")) , or (DISCDATE >= '01JUL2018'D and PAT_DISP in ("50", "51")) then hospice2=1, where PAT_DISP is the Patient Discharge Disposition from CaseMix IP dataset
 - Prior to FY19, 29 = TO ON-SITE HOSPICE, 53 = TO A HOSPICE FACILITY ;
 - From FY19 and onwards, 50 = TO HOSPICE AT HOME, 51 = TO HOSPICE DEFINED AS A MEDICAL FACILITY (CERTIFIED) PROVIDING HOSPICE LEVEL OF CARE (INCLUDES HOSPICE UNIT OF AN ACUTE CARE HOSPITAL)
- If there is a hospice admission 120 days prior to the index IP visit, or 30 days after the index IP visit either in CCLF claims or MD Medicaid claims, then set hospice3=1.
 - hospice3 = (hspc_within_30days_ip=1);
- APR DRG: Maternal and neonatal and ungroupable admissions are excluded based on APR DRG. Excluded codes are: 863, 636, 633, 630, 631, 639, 640, 603, 613, 611, 591, 593, 588, 589, 602, 608, 607, 614, 612, 609, 623, 621, 625, 622, 626, 583, 634, 581, 580, 955, 956, 196, 560, 540
- Disposition: Transfers, Left Against Medical Advice, inconsistent vital status (death prior to admission or prior to discharge if discharged alive) are excluded
- Diagnosis: Any diagnosis of metastatic cancer (**Cancer Diagnosis list provided below**) or a principal diagnosis indicating low survival probability (ICD10=G931 Anoxic brain damage, not elsewhere classified, R403 Persistent vegetative state, A8100 Creutzfeldt-Jakob disease, unspecified, A8109 Other Creutzfeldt-Jakob disease, G9382 Brain death, R092 Respiratory arrest, I469 Cardiac arrest, cause unspecified with a secondary diagnosis of AMI)) are excluded. Crush, spinal or brain injury, and burns are excluded by mapping the principal diagnosis into CCS software as CCS= 234: Crush, 240: Burns, 233: Intracranial injury 227: Spinal cord injury.
- Other: After these exclusions are imposed, a random admission is selected for each patient with multiple stays, other admissions are excluded

Outcome

Death within 30 days is indicated by subtracting the admission date from discharge date with a disposition indicating inpatient death or, if the patient is not discharged dead, from the date of death taken from the vital statistics file or.

Risk adjustment

Risk adjustment is performed by first classifying each stay into one of 15 service categories. The stay is assigned a surgical service category if a major surgical procedure is performed. Otherwise, the stay is nonsurgical. Non-surgical service categories are assigned based on principal diagnosis as mapped into CCS categories. Surgical service categories are assigned based on principal procedure (except Surgical Cancer, which is based on a major surgical procedure and a cancer principal diagnosis), also mapped into CCS categories. **AHRQ CCS categories for these service lines are presented below.**

Non-surgical categories are:

- Non-Surgical: Cancer
- Non-Surgical: Cardiac
- Non-Surgical: Gastrointestinal
- Non-Surgical: Infectious Disease
- Non-Surgical: Neurology
- Non-Surgical: Orthopedics
- Non-Surgical: Pulmonary
- Non-Surgical: Renal
- Non-Surgical: Other

Surgical categories are:

- Surgical: Cancer
- Surgical: Cardiothoracic
- Surgical: Neurosurgery
- Surgical: Other
- Surgical: General

Risk adjustment is performed by estimating logistic regression models for each service category with a random intercept for each index hospital. The risk factors in these models are age and APR DRG-risk of mortality (APR DRG-ROM). In this step, cases for which APR DRG volume is less than 20 are excluded from the model.

Measure

A risk adjusted mortality ratio is calculated separately for each of the 15 service lines. The ratio is the mean predicted probability over the mean expected probability for cases attributed to the hospital during

the study period. Predicted probability is calculated as the probability projected from the model including the hospital's intercept, while expected probability is projected without that intercept.

The hospital's overall risk adjusted rate is the product of the statewide mortality rate, calculated over cases in the analytic file used to generate hospital predicted rates, and the weighted logarithmic mean of risk adjusted rates, where weights are the service line shares of cases for that hospital.

Cancer Exclusions Diagnosis List

C153	Malignant neoplasm of upper third of esophagus
C154	Malignant neoplasm of middle third of esophagus
C155	Malignant neoplasm of lower third of esophagus
C158	Malignant neoplasm of overlapping sites of esophagus
C159	Malignant neoplasm of esophagus, unspecified
C160	Malignant neoplasm of cardia
C161	Malignant neoplasm of fundus of stomach
C162	Malignant neoplasm of body of stomach
C163	Malignant neoplasm of pyloric antrum
C164	Malignant neoplasm of pylorus
C165	Malignant neoplasm of lesser curvature of stomach, unspecified
C166	Malignant neoplasm of greater curvature of stomach, unspecified
C168	Malignant neoplasm of overlapping sites of stomach
C169	Malignant neoplasm of stomach, unspecified
C170	Malignant neoplasm of duodenum
C171	Malignant neoplasm of jejunum
C172	Malignant neoplasm of ileum
C173	Meckel's diverticulum, malignant
C178	Malignant neoplasm of overlapping sites of small intestine
C179	Malignant neoplasm of small intestine, unspecified
C220	Liver cell carcinoma
C221	Intrahepatic bile duct carcinoma
C222	Hepatoblastoma
C223	Angiosarcoma of liver
C224	Other sarcomas of liver
C227	Other specified carcinomas of liver

C228	Malignant neoplasm of liver, primary, unspecified as to type
C229	Malignant neoplasm of liver, not specified as primary or secondary
C23	Malignant neoplasm of gallbladder
C240	Malignant neoplasm of extrahepatic bile duct
C241	Malignant neoplasm of ampulla of Vater
C248	Malignant neoplasm of overlapping sites of biliary tract
C249	Malignant neoplasm of biliary tract, unspecified
C250	Malignant neoplasm of head of pancreas
C251	Malignant neoplasm of body of pancreas
C252	Malignant neoplasm of tail of pancreas
C253	Malignant neoplasm of pancreatic duct
C254	Malignant neoplasm of endocrine pancreas
C257	Malignant neoplasm of other parts of pancreas
C258	Malignant neoplasm of overlapping sites of pancreas
C259	Malignant neoplasm of pancreas, unspecified
C3400	Malignant neoplasm of unspecified main bronchus
C3401	Malignant neoplasm of right main bronchus
C3402	Malignant neoplasm of left main bronchus
C3410	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C3411	Malignant neoplasm of upper lobe, right bronchus or lung
C3412	Malignant neoplasm of upper lobe, left bronchus or lung
C342	Malignant neoplasm of middle lobe, bronchus or lung
C3430	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C3431	Malignant neoplasm of lower lobe, right bronchus or lung
C3432	Malignant neoplasm of lower lobe, left bronchus or lung
C3480	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C3481	Malignant neoplasm of overlapping sites of right bronchus and lung
C3482	Malignant neoplasm of overlapping sites of left bronchus and lung
C3490	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C3491	Malignant neoplasm of unspecified part of right bronchus or lung
C3492	Malignant neoplasm of unspecified part of left bronchus or lung
C37	Malignant neoplasm of thymus
C380	Malignant neoplasm of heart

C381	Malignant neoplasm of anterior mediastinum
C382	Malignant neoplasm of posterior mediastinum
C383	Malignant neoplasm of mediastinum, part unspecified
C384	Malignant neoplasm of pleura
C388	Malignant neoplasm of overlapping sites of heart, mediastinum and
C390	Malignant neoplasm of upper respiratory tract, part unspecified
C399	Malignant neoplasm of lower respiratory tract, part unspecified
C450	Mesothelioma of pleura
C452	Mesothelioma of pericardium
C459	Mesothelioma, unspecified
C700	Malignant neoplasm of cerebral meninges
C701	Malignant neoplasm of spinal meninges
C709	Malignant neoplasm of meninges, unspecified
C710	Malignant neoplasm of cerebrum, except lobes and ventricles
C711	Malignant neoplasm of frontal lobe
C712	Malignant neoplasm of temporal lobe
C713	Malignant neoplasm of parietal lobe
C714	Malignant neoplasm of occipital lobe
C715	Malignant neoplasm of cerebral ventricle
C716	Malignant neoplasm of cerebellum
C717	Malignant neoplasm of brain stem
C718	Malignant neoplasm of overlapping sites of brain
C719	Malignant neoplasm of brain, unspecified
C720	Malignant neoplasm of spinal cord
C721	Malignant neoplasm of cauda equina
C7220	Malignant neoplasm of unspecified olfactory nerve
C7221	Malignant neoplasm of right olfactory nerve
C7222	Malignant neoplasm of left olfactory nerve
C7230	Malignant neoplasm of unspecified optic nerve
C7231	Malignant neoplasm of right optic nerve
C7232	Malignant neoplasm of left optic nerve
C7240	Malignant neoplasm of unspecified acoustic nerve
C7241	Malignant neoplasm of right acoustic nerve

C7242	Malignant neoplasm of left acoustic nerve
C7250	Malignant neoplasm of unspecified cranial nerve
C7259	Malignant neoplasm of other cranial nerves
C729	Malignant neoplasm of central nervous system, unspecified
C770	Secondary and unspecified malignant neoplasm of lymph nodes of head
C771	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C772	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C773	Secondary and unspecified malignant neoplasm of axilla and upper limb
C774	Secondary and unspecified malignant neoplasm of inguinal and lower limb
C775	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C778	Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites
C779	Secondary and unspecified malignant neoplasm of lymph node, unspecified
C7800	Secondary malignant neoplasm of unspecified lung
C7801	Secondary malignant neoplasm of right lung
C7802	Secondary malignant neoplasm of left lung
C781	Secondary malignant neoplasm of mediastinum
C782	Secondary malignant neoplasm of pleura
C7830	Secondary malignant neoplasm of unspecified respiratory organ
C7839	Secondary malignant neoplasm of other respiratory organs
C784	Secondary malignant neoplasm of small intestine
C785	Secondary malignant neoplasm of large intestine and rectum
C786	Secondary malignant neoplasm of retroperitoneum and peritoneum
C787	Secondary malignant neoplasm of liver and intrahepatic bile duct
C7880	Secondary malignant neoplasm of unspecified digestive organ
C7889	Secondary malignant neoplasm of other digestive organs
C7900	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C7901	Secondary malignant neoplasm of right kidney and renal pelvis
C7902	Secondary malignant neoplasm of left kidney and renal pelvis
C7910	Secondary malignant neoplasm of unspecified urinary organs
C7911	Secondary malignant neoplasm of bladder
C7919	Secondary malignant neoplasm of other urinary organs
C792	Secondary malignant neoplasm of skin
C7931	Secondary malignant neoplasm of brain

C7932	Secondary malignant neoplasm of cerebral meninges
C7940	Secondary malignant neoplasm of unsp part of nervous system
C7949	Secondary malignant neoplasm of oth parts of nervous system
C7951	Secondary malignant neoplasm of bone
C7952	Secondary malignant neoplasm of bone marrow
C7960	Secondary malignant neoplasm of unspecified ovary
C7961	Secondary malignant neoplasm of right ovary
C7962	Secondary malignant neoplasm of left ovary
C7970	Secondary malignant neoplasm of unspecified adrenal gland
C7971	Secondary malignant neoplasm of right adrenal gland
C7972	Secondary malignant neoplasm of left adrenal gland
C7981	Secondary malignant neoplasm of breast
C7982	Secondary malignant neoplasm of genital organs
C7989	Secondary malignant neoplasm of other specified sites
C799	Secondary malignant neoplasm of unspecified site
C7A00	Malignant carcinoid tumor of unspecified site
C7A010	Malignant carcinoid tumor of the duodenum
C7A011	Malignant carcinoid tumor of the jejunum
C7A012	Malignant carcinoid tumor of the ileum
C7A019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A020	Malignant carcinoid tumor of the appendix
C7A021	Malignant carcinoid tumor of the cecum
C7A022	Malignant carcinoid tumor of the ascending colon
C7A023	Malignant carcinoid tumor of the transverse colon
C7A024	Malignant carcinoid tumor of the descending colon
C7A025	Malignant carcinoid tumor of the sigmoid colon
C7A026	Malignant carcinoid tumor of the rectum
C7A029	Malignant carcinoid tumor of the large intestine, unspecified portion
C7A090	Malignant carcinoid tumor of the bronchus and lung
C7A091	Malignant carcinoid tumor of the thymus
C7A092	Malignant carcinoid tumor of the stomach
C7A093	Malignant carcinoid tumor of the kidney
C7A094	Malignant carcinoid tumor of the foregut, unspecified

C7A095	Malignant carcinoid tumor of the midgut, unspecified
C7A096	Malignant carcinoid tumor of the hindgut, unspecified
C7A098	Malignant carcinoid tumors of other sites
C7A1	Malignant poorly differentiated neuroendocrine tumors
C7A8	Other malignant neuroendocrine tumors
C7B00	Secondary carcinoid tumors, unspecified site
C7B01	Secondary carcinoid tumors of distant lymph nodes
C7B02	Secondary carcinoid tumors of liver
C7B03	Secondary carcinoid tumors of bone
C7B04	Secondary carcinoid tumors of peritoneum
C7B09	Secondary carcinoid tumors of other sites
C7B1	Secondary Merkel cell carcinoma
C800	Disseminated malignant neoplasm, unspecified
J910	Malignant pleural effusion

AHRQ CCS Categories by Service Line

Defining Surgical Procedure	AHRQ CCS	CCS Description	Surgical Division of Procedure
36	Lobectomy or pneumonectomy	Cardiothoracic	
42	Other OR Rx procedures on respiratory system and mediastinum		Cardiothoracic
43	Heart valve procedures	Cardiothoracic	
44	Coronary artery bypass graft (CABG)	Cardiothoracic	
49	Other OR heart procedures	Cardiothoracic	
66	Procedures on spleen	General	
67	Other therapeutic procedures; hemic and lymphatic system		General
72	Colostomy; temporary and permanent	General	
73	Ileostomy and other enterostomy	General	
74	Gastrectomy; partial and total	General	
75	Small bowel resection	General	
78	Colorectal resection	General	
79	Local excision of large intestine lesion (not endoscopic)		General

80	Appendectomy	General	
84	Cholecystectomy and common duct exploration		General
85	Inguinal and femoral hernia repair	General	
86	Other hernia repair	General	
89	Exploratory laparotomy	General	
90	Excision; lysis peritoneal adhesions	General	
94	Other OR upper GI therapeutic procedures	General	
96	Other OR lower GI therapeutic procedures	General	
99	Other OR gastrointestinal therapeutic procedures	General	
105	Kidney transplant	General	
166	Lumpectomy; quadrantectomy of breast	General	
167	Mastectomy	General	
176	Organ transplantation (other than bone marrow, corneal or kidney)		General
10	Thyroidectomy; partial or complete	Other	
12	Other therapeutic endocrine procedures	Other	
13	Corneal transplant	Other	
14	Glaucoma procedures	Other	
15	Lens and cataract procedures	Other	
16	Repair of retinal tear; detachment	Other	
17	Destruction of lesion of retina and choroid	Other	
20	Other intraocular therapeutic procedures	Other	
21	Other extraocular muscle and orbit therapeutic procedures	Other	
22	Tympanoplasty	Other	
23	Myringotomy	Other	
24	Mastoidectomy	Other	
26	Other therapeutic ear procedures	Other	
28	Plastic procedures on nose	Other	
30	Tonsillectomy and/or adenoidectomy	Other	
33	Other OR therapeutic procedures on nose; mouth and pharynx		Other
51	Endarterectomy; vessel of head and neck	Other	
52	Aortic resection; replacement or anastomosis		Other
53	Varicose vein stripping; lower limb	Other	
55	Peripheral vascular bypass	Other	

56	Other vascular bypass and shunt; not heart	Other	
59	Other OR procedures on vessels of head and neck	Other	
60	Embolectomy and endarterectomy of lower limbs	Other	
101	Transurethral excision; drainage; or removal urinary obstruction		Other
103	Nephrotomy and nephrostomy	Other	
104	Nephrectomy; partial or complete	Other	
106	Genitourinary incontinence procedures	Other	
112	Other OR therapeutic procedures of urinary tract	Other	
113	Transurethral resection of prostate (TURP)	Other	
114	Open prostatectomy	Other	
118	Other OR therapeutic procedures; male genital	Other	
119	Oophorectomy; unilateral and bilateral	Other	
120	Other operations on ovary	Other	
123	Other operations on fallopian tubes	Other	
124	Hysterectomy; abdominal and vaginal	Other	
125	Other excision of cervix and uterus	Other	
129	Repair of cystocele and rectocele; obliteration of vaginal vault		Other
131	Other non-OR therapeutic procedures; female organs	Other	
132	Other OR therapeutic procedures; female organs	Other	
135	Forceps; vacuum; and breech delivery	Other	
144	Treatment; facial fracture or dislocation	Other	
160	Other therapeutic procedures on muscles and tendons	Other	
164	Other OR therapeutic procedures on musculoskeletal system		Other
172	Skin graft	Other	
175	Other OR therapeutic procedures on skin and breast	Other	
1	Incision and excision of CNS	Neurosurgery	
2	Insertion; replacement; or removal of extracranial ventricular shunt		Neurosurgery
9	Other OR therapeutic nervous system procedures	Neurosurgery	
3	Laminectomy; excision intervertebral disc	Orthopedic	
142	Partial excision bone	Orthopedic	
143	Bunionectomy or repair of toe deformities	Orthopedic	
145	Treatment; fracture or dislocation of radius and ulna	Orthopedic	
146	Treatment; fracture or dislocation of hip and femur	Orthopedic	

147	Treatment; fracture or dislocation of lower extremity (other than hip or femur)	
Orthopedic		
148	Other fracture and dislocation procedure	Orthopedic
150	Division of joint capsule; ligament or cartilage	Orthopedic
151	Excision of semilunar cartilage of knee	Orthopedic
152	Arthroplasty knee	Orthopedic
153	Hip replacement; total and partial	Orthopedic
154	Arthroplasty other than hip or knee	Orthopedic
157	Amputation of lower extremity	Orthopedic
158	Spinal fusion	Orthopedic
161	Other OR therapeutic procedures on bone	Orthopedic
162	Other OR therapeutic procedures on joints	Orthopedic

AHRQ Diagnosis CCS	Description	Non-Surgical Division
11	Cancer of head and neck	Cancer
12	Cancer of esophagus	Cancer
13	Cancer of stomach	Cancer
14	Cancer of colon	Cancer
15	Cancer of rectum and anus	Cancer
16	Cancer of liver and intrahepatic bile duct	Cancer
17	Cancer of pancreas	Cancer
18	Cancer of other GI organs; peritoneum	Cancer
19	Cancer of bronchus; lung	Cancer
20	Cancer; other respiratory and intrathoracic	Cancer
21	Cancer of bone and connective tissue	Cancer
22	Melanomas of skin	Cancer
23	Other non-epithelial cancer of skin	Cancer
24	Cancer of breast	Cancer
25	Cancer of uterus	Cancer
26	Cancer of cervix	Cancer
27	Cancer of ovary	Cancer
28	Cancer of other female genital organs	Cancer

29	Cancer of prostate	Cancer
30	Cancer of testis	Cancer
31	Cancer of other male genital organs	Cancer
32	Cancer of bladder	Cancer
33	Cancer of kidney and renal pelvis	Cancer
34	Cancer of other urinary organs	Cancer
35	Cancer of brain and nervous system	Cancer
36	Cancer of thyroid	Cancer
37	Hodgkin`s disease	Cancer
38	Non-Hodgkin`s lymphoma	Cancer
39	Leukemias	Cancer
40	Multiple myeloma	Cancer
41	Cancer; other and unspecified primary	Cancer
43	Malignant neoplasm without specification of site	Cancer
44	Neoplasms of unspecified nature or uncertain behavior	Cancer
45	Maintenance chemotherapy; radiotherapy	Cancer
96	Heart valve disorders	Cardiac
97	Peri-; endo-; and myocarditis; cardiomyopathy (except that caused by tuberculosis or sexually transmitted disease)	Cardiac
100	Acute myocardial infarction	Cardiac
101	Coronary atherosclerosis and other heart disease	Cardiac
102	Nonspecific chest pain	Cardiac
103	Pulmonary heart disease	Cardiac
104	Other and ill-defined heart disease	Cardiac
105	Conduction disorders	Cardiac
106	Cardiac dysrhythmias	Cardiac
107	Cardiac arrest and ventricular fibrillation	Cardiac
108	Congestive heart failure; nonhypertensive	Cardiac
213	Cardiac and circulatory congenital anomalies	Cardiac
245	Syncope	Cardiac
249	Shock	Cardiac
6	Hepatitis	Gastrointestinal
120	Hemorrhoids	Gastrointestinal

138	Esophageal disorders	Gastrointestinal
139	Gastroduodenal ulcer (except hemorrhage)	Gastrointestinal
140	Gastritis and duodenitis	Gastrointestinal
141	Other disorders of stomach and duodenum	Gastrointestinal
142	Appendicitis and other appendiceal conditions	Gastrointestinal
143	Abdominal hernia	Gastrointestinal
144	Regional enteritis and ulcerative colitis	Gastrointestinal
145	Intestinal obstruction without hernia	Gastrointestinal
146	Diverticulosis and diverticulitis	Gastrointestinal
147	Anal and rectal conditions	Gastrointestinal
148	Peritonitis and intestinal abscess	Gastrointestinal
149	Biliary tract disease	Gastrointestinal
150	Liver disease; alcohol related	Gastrointestinal
151	Other liver diseases	Gastrointestinal
152	Pancreatic disorders (not diabetes)	Gastrointestinal
153	Gastrointestinal hemorrhage	Gastrointestinal
154	Noninfectious gastroenteritis	Gastrointestinal
155	Other gastrointestinal disorders	Gastrointestinal
214	Digestive congenital anomalies	Gastrointestinal
250	Nausea and vomiting	Gastrointestinal
251	Abdominal pain	Gastrointestinal
1	Tuberculosis	Infectious Disease
2	Septicemia (except in labor)	Infectious Disease
3	Bacterial infection; unspecified site	Infectious Disease
4	Mycoses	Infectious Disease
5	HIV infection	Infectious Disease
7	Viral infection	Infectious Disease
8	Other infections; including parasitic	Infectious Disease
9	Sexually transmitted infections (not HIV or hepatitis)	Infectious Disease
76	Meningitis (except that caused by tuberculosis or sexually transmitted disease)	
	Infectious Disease	
77	Encephalitis (except that caused by tuberculosis or sexually transmitted disease)	
	Infectious Disease	

135	Intestinal infection	Infectious Disease
159	Urinary tract infections	Infectious Disease
197	Skin and subcutaneous tissue infections	Infectious Disease
201	Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted disease)	Infectious Disease
246	Fever of unknown origin	Infectious Disease
237	Complication of device; implant or graft	Other Conditions
238	Complications of surgical procedures or medical care	Other Conditions
198	Other inflammatory condition of skin	Other Conditions
199	Chronic ulcer of skin	Other Conditions
200	Other skin disorders	Other Conditions
48	Thyroid disorders	Other Conditions
49	Diabetes mellitus without complication	Other Conditions
50	Diabetes mellitus with complications	Other Conditions
51	Other endocrine disorders	Other Conditions
53	Disorders of lipid metabolism	Other Conditions
58	Other nutritional; endocrine; and metabolic disorders	Other Conditions
206	Osteoporosis	Other Conditions
92	Otitis media and related conditions	Other Conditions
94	Other ear and sense organ disorders	Other Conditions
124	Acute and chronic tonsillitis	Other Conditions
134	Other upper respiratory disease	Other Conditions
136	Disorders of teeth and jaw	Other Conditions
137	Diseases of mouth; excluding dental	Other Conditions
46	Benign neoplasm of uterus	Other Conditions
160	Calculus of urinary tract	Other Conditions
161	Other diseases of kidney and ureters	Other Conditions
162	Other diseases of bladder and urethra	Other Conditions
163	Genitourinary symptoms and ill-defined conditions	Other Conditions
164	Hyperplasia of prostate	Other Conditions
165	Inflammatory conditions of male genital organs	Other Conditions
166	Other male genital disorders	Other Conditions
167	Nonmalignant breast conditions	Other Conditions

168	Inflammatory diseases of female pelvic organs	Other Conditions
169	Endometriosis	Other Conditions
170	Prolapse of female genital organs	Other Conditions
171	Menstrual disorders	Other Conditions
172	Ovarian cyst	Other Conditions
173	Menopausal disorders	Other Conditions
174	Female infertility	Other Conditions
175	Other female genital disorders	Other Conditions
215	Genitourinary congenital anomalies	Other Conditions
59	Deficiency and other anemia	Other Conditions
60	Acute posthemorrhagic anemia	Other Conditions
61	Sickle cell anemia	Other Conditions
62	Coagulation and hemorrhagic disorders	Other Conditions
63	Diseases of white blood cells	Other Conditions
64	Other hematologic conditions	Other Conditions
247	Lymphadenitis	Other Conditions
54	Gout and other crystal arthropathies	Other Conditions
57	Immunity disorders	Other Conditions
202	Rheumatoid arthritis and related disease	Other Conditions
210	Systemic lupus erythematosus and connective tissue disorders	Other Conditions
211	Other connective tissue disease	Other Conditions
253	Allergic reactions	Other Conditions
84	Headache; including migraine	Other Conditions
93	Conditions associated with dizziness or vertigo	Other Conditions
10	Immunizations and screening for infectious disease	Other Conditions
47	Other and unspecified benign neoplasm	Other Conditions
52	Nutritional deficiencies	Other Conditions
217	Other congenital anomalies	Other Conditions
252	Malaise and fatigue	Other Conditions
255	Administrative/social admission	Other Conditions
256	Medical examination/evaluation	Other Conditions
257	Other aftercare	Other Conditions

258	Other screening for suspected conditions (not mental disorders or infectious disease)	
Other Conditions		
259	Residual codes; unclassified	Other Conditions
86	Cataract	Other Conditions
87	Retinal detachments; defects; vascular occlusion; and retinopathy	Other Conditions
88	Glaucoma	Other Conditions
89	Blindness and vision defects	Other Conditions
90	Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted disease)	Other Conditions
91	Other eye disorders	Other Conditions
653	Delirium, dementia, and amnesic and other cognitive disorders	Other Conditions
241	Poisoning by psychotropic agents	Other Conditions
242	Poisoning by other medications and drugs	Other Conditions
243	Poisoning by nonmedicinal substances	Other Conditions
660	Alcohol-related disorders	Other Conditions
661	Substance-related disorders	Other Conditions
663	Screening and history of mental health and substance abuse codes	Other Conditions
114	Peripheral and visceral atherosclerosis	Other Conditions
115	Aortic; peripheral; and visceral artery aneurysms	Other Conditions
116	Aortic and peripheral arterial embolism or thrombosis	Other Conditions
117	Other circulatory disease	Other Conditions
118	Phlebitis; thrombophlebitis and thromboembolism	Other Conditions
119	Varicose veins of lower extremity	Other Conditions
121	Other diseases of veins and lymphatics	Other Conditions
248	Gangrene	Other Conditions
78	Other CNS infection and poliomyelitis	Neurology
79	Parkinson`s disease	Neurology
80	Multiple sclerosis	Neurology
81	Other hereditary and degenerative nervous system conditions	Neurology
82	Paralysis	Neurology
83	Epilepsy; convulsions	Neurology
85	Coma; stupor; and brain damage	Neurology
95	Other nervous system disorders	Neurology

109	Acute cerebrovascular disease	Neurology	
110	Occlusion or stenosis of precerebral arteries	Neurology	
111	Other and ill-defined cerebrovascular disease	Neurology	
112	Transient cerebral ischemia	Neurology	
113	Late effects of cerebrovascular disease	Neurology	
216	Nervous system congenital anomalies	Neurology	
235	Open wounds of head; neck; and trunk	Orthopedics	
236	Open wounds of extremities	Orthopedics	
239	Superficial injury; contusion	Orthopedics	
244	Other injuries and conditions due to external causes	Orthopedics	
203	Osteoarthritis	Orthopedics	
204	Other non-traumatic joint disorders	Orthopedics	
205	Spondylosis; intervertebral disc disorders; other back problems	Orthopedics	Orthopedics
207	Pathological fracture	Orthopedics	
208	Acquired foot deformities	Orthopedics	
209	Other acquired deformities	Orthopedics	Orthopedics
212	Other bone disease and musculoskeletal deformities	Orthopedics	
225	Joint disorders and dislocations; trauma-related	Orthopedics	
226	Fracture of neck of femur (hip)	Orthopedics	
228	Skull and face fractures	Orthopedics	
229	Fracture of upper limb	Orthopedics	
230	Fracture of lower limb	Orthopedics	
231	Other fractures	Orthopedics	
232	Sprains and strains	Orthopedics	
56	Cystic fibrosis	Pulmonary	
122	Pneumonia (except that caused by tuberculosis or sexually transmitted disease)	Pulmonary	
123	Influenza	Pulmonary	
125	Acute bronchitis	Pulmonary	
126	Other upper respiratory infections	Pulmonary	
127	Chronic obstructive pulmonary disease and bronchiectasis	Pulmonary	
128	Asthma	Pulmonary	
129	Aspiration pneumonitis; food/vomitus	Pulmonary	

130	Pleurisy; pneumothorax; pulmonary collapse	Pulmonary
131	Respiratory failure; insufficiency; arrest (adult)	Pulmonary
132	Lung disease due to external agents	Pulmonary
133	Other lower respiratory disease	Pulmonary
55	Fluid and electrolyte disorders	Renal
98	Essential hypertension	Renal
99	Hypertension with complications and secondary hypertension	Renal
156	Nephritis; nephrosis; renal sclerosis	Renal
157	Acute and unspecified renal failure	Renal
158	Chronic kidney disease	Renal

Appendix B: RY 2027 QBR Preset Payment Scale

Final QBR Score		QBR Preset Scale
Scores less than or equal to	0%	-2.00%
	1%	-1.94%
	2%	-1.88%
	3%	-1.81%
	4%	-1.75%
	5%	-1.69%
	6%	-1.63%
	7%	-1.56%
	8%	-1.50%
	9%	-1.44%
	10%	-1.38%
	11%	-1.31%
	12%	-1.25%
	13%	-1.19%
	14%	-1.13%
	15%	-1.06%
	16%	-1.00%
	17%	-0.94%
	18%	-0.88%
	19%	-0.81%
	20%	-0.75%
	21%	-0.69%
	22%	-0.63%
	23%	-0.56%
	24%	-0.50%
	25%	-0.44%
	26%	-0.38%
	27%	-0.31%
	28%	-0.25%
	29%	-0.19%
	30%	-0.13%
	31%	-0.06%
	32%	0.00%
	33%	0.04%
	34%	0.08%
	35%	0.13%
	36%	0.17%
	37%	0.21%
	38%	0.25%
	39%	0.29%

Final QBR Score	QBR Preset Scale
	40%
	0.33%
	41%
	0.38%
	42%
	0.42%
	43%
	0.46%
	44%
	0.50%
	45%
	0.54%
	46%
	0.58%
	47%
	0.63%
	48%
	0.67%
	49%
	0.71%
	50%
	0.75%
	51%
	0.79%
	52%
	0.83%
	53%
	0.88%
	54%
	0.92%
	55%
	0.96%
	56%
	1.00%
	57%
	1.04%
	58%
	1.08%
	59%
	1.13%
	60%
	1.17%
	61%
	1.21%
	62%
	1.25%
	63%
	1.29%
	64%
	1.33%
	65%
	1.38%
	66%
	1.42%
	67%
	1.46%
	68%
	1.50%
	69%
	1.54%
	70%
	1.58%
	71%
	1.63%
	72%
	1.67%
	73%
	1.71%
	74%
	1.75%
	75%
	1.79%
	76%
	1.83%
	77%
	1.88%
	78%
	1.92%
	79%
	1.96%
Scores greater than or equal to	80%
	2.00%

*For RY 2028, hospitals earning a score of less than 32% (0.32) will receive a penalty, and hospitals earning a score of 0.32 and above will receive a reward. Any hospital earning a score of 0.80 or higher will receive the maximum reward of 2% of their inpatient revenue. This “cut-point” will be re-evaluated retrospectively.